Brokers Issue Forecasts for FibroGen, Inc.’s Q2 2022 Earnings (NASDAQ:FGEN)

FibroGen, Inc. (NASDAQ:FGENGet Rating) – Jefferies Financial Group raised their Q2 2022 earnings estimates for FibroGen in a research note issued on Monday, May 9th. Jefferies Financial Group analyst M. Yee now anticipates that the biopharmaceutical company will post earnings per share of ($0.94) for the quarter, up from their prior forecast of ($1.03). Jefferies Financial Group also issued estimates for FibroGen’s Q3 2022 earnings at ($0.98) EPS, Q4 2022 earnings at ($1.02) EPS, FY2022 earnings at ($3.63) EPS and FY2023 earnings at ($3.03) EPS.

A number of other equities analysts have also recently weighed in on FGEN. StockNews.com began coverage on FibroGen in a report on Thursday, March 31st. They set a “hold” rating on the stock. The Goldman Sachs Group dropped their target price on FibroGen from $10.00 to $9.00 and set a “sell” rating on the stock in a report on Tuesday, March 1st. Finally, Zacks Investment Research raised FibroGen from a “strong sell” rating to a “hold” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.43.

Shares of NASDAQ FGEN opened at $9.94 on Thursday. FibroGen has a 52 week low of $7.81 and a 52 week high of $30.12. The business has a 50-day simple moving average of $11.48 and a two-hundred day simple moving average of $13.00. The company has a market cap of $927.38 million, a P/E ratio of -3.27 and a beta of 0.91.

FibroGen (NASDAQ:FGENGet Rating) last released its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.16. FibroGen had a negative return on equity of 109.09% and a negative net margin of 109.22%. The business had revenue of $60.80 million during the quarter, compared to analyst estimates of $28.76 million. During the same period in the prior year, the firm posted ($0.78) EPS. FibroGen’s quarterly revenue was up 58.3% compared to the same quarter last year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. National Bank of Canada FI purchased a new position in shares of FibroGen in the fourth quarter worth approximately $33,000. Dixon Hughes Goodman Wealth Advisors LLC purchased a new position in shares of FibroGen in the first quarter worth approximately $59,000. Point72 Hong Kong Ltd purchased a new position in shares of FibroGen in the third quarter worth approximately $65,000. Royal Bank of Canada boosted its holdings in shares of FibroGen by 20.6% in the third quarter. Royal Bank of Canada now owns 7,451 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 1,271 shares during the last quarter. Finally, Advisor Group Holdings Inc. boosted its holdings in shares of FibroGen by 90.6% in the fourth quarter. Advisor Group Holdings Inc. now owns 8,909 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 4,236 shares during the last quarter. 77.35% of the stock is currently owned by institutional investors.

About FibroGen (Get Rating)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Read More

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.